HEADER TRANSFERASE/TRANSFERASE INHIBITOR 17-JAN-11 3QD3 TITLE PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 1,1- TITLE 2 DIMETHYLETHYL {(3R,6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- TITLE 3 PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE COMPND MOL_ID: 1; COMPND 2 MOLECULE: 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: KINASE DOMAIN, RESIDUES 48-359; COMPND 5 SYNONYM: HPDK1; COMPND 6 EC: 2.7.11.1; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PDK1, PDPK1; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 7108 KEYWDS KINASE DOMAIN, AGC KINASE, SIGNAL TRANDUCTION, ATP & KEYWDS 2 PHOSPHOINOSITIDE, PHOSPHORYLATION ON S241, TRANSFERASE-TRANSFERASE KEYWDS 3 INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR J.R.MEDINA,C.J.BECKER,C.W.BLACKLEDGE,C.DUQUENNE,Y.FENG,S.W.GRANT, AUTHOR 2 D.HEERDING,W.H.LI,W.H.MILLER,S.P.ROMERIL,D.SCHERZER,A.SHU,M.A.BOBKO, AUTHOR 3 A.R.CHADDERTON,M.DUMBLE,C.M.GRADINER,S.GILBERT,Q.LIU,S.K.RABINDRAN, AUTHOR 4 V.SUDAKIN,H.XIANG,P.G.BRADY,N.CAMPOBASSO,P.WARD,J.M.AXTEN REVDAT 3 30-OCT-24 3QD3 1 REMARK LINK REVDAT 2 30-MAR-11 3QD3 1 JRNL REVDAT 1 09-MAR-11 3QD3 0 JRNL AUTH J.R.MEDINA,C.J.BECKER,C.W.BLACKLEDGE,C.DUQUENNE,Y.FENG, JRNL AUTH 2 S.W.GRANT,D.HEERDING,W.H.LI,W.H.MILLER,S.P.ROMERIL, JRNL AUTH 3 D.SCHERZER,A.SHU,M.A.BOBKO,A.R.CHADDERTON,M.DUMBLE, JRNL AUTH 4 C.M.GARDINER,S.GILBERT,Q.LIU,S.K.RABINDRAN,V.SUDAKIN, JRNL AUTH 5 H.XIANG,P.G.BRADY,N.CAMPOBASSO,P.WARD,J.M.AXTEN JRNL TITL STRUCTURE-BASED DESIGN OF POTENT AND SELECTIVE JRNL TITL 2 3-PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) INHIBITORS. JRNL REF J.MED.CHEM. V. 54 1871 2011 JRNL REFN ISSN 0022-2623 JRNL PMID 21341675 JRNL DOI 10.1021/JM101527U REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH J.R.MEDINA,C.W.BLACKLEDGE,D.A.HEERDING,N.CAMPOBASSO,P.WARD, REMARK 1 AUTH 2 J.BRIAND,L.WRIGHT,J.M.AXTEN REMARK 1 TITL AMINOINDAZOLE PDK1 INHIBITORS: A CASE STUDY IN REMARK 1 TITL 2 FRAGMENT-BASED DRUG DISCOVERY REMARK 1 REF ACS MED. CHEM. LETT. V. 1 439 2010 REMARK 1 REFN ISSN 1948-5875 REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.4_87 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.67 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 0.050 REMARK 3 COMPLETENESS FOR RANGE (%) : 96.1 REMARK 3 NUMBER OF REFLECTIONS : 26925 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.185 REMARK 3 R VALUE (WORKING SET) : 0.183 REMARK 3 FREE R VALUE : 0.211 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 7.220 REMARK 3 FREE R VALUE TEST SET COUNT : 1943 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 29.6749 - 4.8135 1.00 1936 155 0.2054 0.2106 REMARK 3 2 4.8135 - 3.8232 1.00 1887 145 0.1569 0.1720 REMARK 3 3 3.8232 - 3.3407 1.00 1843 144 0.1703 0.2125 REMARK 3 4 3.3407 - 3.0356 0.99 1859 143 0.1914 0.2076 REMARK 3 5 3.0356 - 2.8182 0.98 1816 141 0.1843 0.2262 REMARK 3 6 2.8182 - 2.6521 0.98 1832 135 0.1809 0.1922 REMARK 3 7 2.6521 - 2.5194 0.97 1785 140 0.1871 0.2339 REMARK 3 8 2.5194 - 2.4098 0.97 1781 142 0.1779 0.2308 REMARK 3 9 2.4098 - 2.3170 0.96 1768 136 0.1806 0.2213 REMARK 3 10 2.3170 - 2.2371 0.94 1725 133 0.1768 0.2129 REMARK 3 11 2.2371 - 2.1672 0.93 1725 136 0.1749 0.2099 REMARK 3 12 2.1672 - 2.1052 0.92 1697 135 0.1773 0.2256 REMARK 3 13 2.1052 - 2.0498 0.91 1674 128 0.1958 0.2362 REMARK 3 14 2.0498 - 2.0000 0.90 1654 130 0.2054 0.2643 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : 0.40 REMARK 3 B_SOL : 52.64 REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.220 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : NULL REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 25.59 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.65430 REMARK 3 B22 (A**2) : -0.65430 REMARK 3 B33 (A**2) : 1.30860 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.007 2386 REMARK 3 ANGLE : 1.171 3226 REMARK 3 CHIRALITY : 0.091 349 REMARK 3 PLANARITY : 0.005 408 REMARK 3 DIHEDRAL : 16.428 878 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 3QD3 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 20-JAN-11. REMARK 100 THE DEPOSITION ID IS D_1000063492. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 08-JUL-09 REMARK 200 TEMPERATURE (KELVIN) : NULL REMARK 200 PH : 9 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 21-ID-F REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97872 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : DIAMOND REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 225 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 28038 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 200 DATA REDUNDANCY : 7.400 REMARK 200 R MERGE (I) : 0.10100 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 9.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.07 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 7.10 REMARK 200 R MERGE FOR SHELL (I) : 0.57300 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 57.52 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.90 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1.9-2 M AMMONIUM SULFATE,0.1 M TRIS PH REMARK 280 9. AND 5MM ATP; 15-30% GLYCEROL PLUS MOTHER LIQUOR MIXED WITH REMARK 280 INHIBITOR SERVED AS THE CRYO-PROTECTANT BEFORE BEING FROZEN IN REMARK 280 LIQUID NITROGEN, VAPOR DIFFUSION. SITTING DROP, TEMPERATURE 293K, REMARK 280 VAPOR DIFFUSION, SITTING DROP REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 32 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+2/3 REMARK 290 3555 -X+Y,-X,Z+1/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+1/3 REMARK 290 6555 -X,-X+Y,-Z+2/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 31.24667 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 15.62333 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 15.62333 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 31.24667 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 48 REMARK 465 PRO A 49 REMARK 465 ALA A 50 REMARK 465 MET A 51 REMARK 465 ASP A 52 REMARK 465 GLY A 53 REMARK 465 THR A 54 REMARK 465 ALA A 55 REMARK 465 ALA A 56 REMARK 465 GLU A 57 REMARK 465 PRO A 58 REMARK 465 ARG A 59 REMARK 465 PRO A 60 REMARK 465 GLY A 61 REMARK 465 ALA A 62 REMARK 465 GLY A 63 REMARK 465 SER A 64 REMARK 465 LEU A 65 REMARK 465 GLN A 66 REMARK 465 HIS A 67 REMARK 465 ALA A 68 REMARK 465 GLN A 69 REMARK 465 PRO A 70 REMARK 465 PRO A 232 REMARK 465 GLU A 233 REMARK 465 SER A 234 REMARK 465 LYS A 235 REMARK 465 GLN A 236 REMARK 465 ALA A 237 REMARK 465 ARG A 238 REMARK 465 ALA A 239 REMARK 465 ASN A 240 REMARK 465 THR A 359 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 73 CG CD OE1 NE2 REMARK 470 ARG A 75 CG CD NE CZ NH1 NH2 REMARK 470 GLU A 303 CG CD OE1 OE2 REMARK 470 LYS A 304 CG CD CE NZ REMARK 470 GLU A 348 CG CD OE1 OE2 REMARK 470 LYS A 357 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 151 -164.19 -119.38 REMARK 500 ARG A 204 -8.58 76.92 REMARK 500 ASP A 205 43.07 -145.16 REMARK 500 ASP A 223 78.84 75.08 REMARK 500 GLU A 256 -20.86 -165.12 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 3Q5 A 360 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 361 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 362 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3NUN RELATED DB: PDB REMARK 900 RELATED ID: 3NUS RELATED DB: PDB REMARK 900 RELATED ID: 3NUU RELATED DB: PDB REMARK 900 RELATED ID: 3NUY RELATED DB: PDB REMARK 900 RELATED ID: 3QCQ RELATED DB: PDB REMARK 900 RELATED ID: 3QCS RELATED DB: PDB REMARK 900 RELATED ID: 3QCX RELATED DB: PDB REMARK 900 RELATED ID: 3QCY RELATED DB: PDB REMARK 900 RELATED ID: 3QD0 RELATED DB: PDB REMARK 900 RELATED ID: 3QD4 RELATED DB: PDB DBREF 3QD3 A 48 359 UNP O15530 PDPK1_HUMAN 48 359 SEQRES 1 A 312 GLY PRO ALA MET ASP GLY THR ALA ALA GLU PRO ARG PRO SEQRES 2 A 312 GLY ALA GLY SER LEU GLN HIS ALA GLN PRO PRO PRO GLN SEQRES 3 A 312 PRO ARG LYS LYS ARG PRO GLU ASP PHE LYS PHE GLY LYS SEQRES 4 A 312 ILE LEU GLY GLU GLY SER PHE SER THR VAL VAL LEU ALA SEQRES 5 A 312 ARG GLU LEU ALA THR SER ARG GLU TYR ALA ILE LYS ILE SEQRES 6 A 312 LEU GLU LYS ARG HIS ILE ILE LYS GLU ASN LYS VAL PRO SEQRES 7 A 312 TYR VAL THR ARG GLU ARG ASP VAL MET SER ARG LEU ASP SEQRES 8 A 312 HIS PRO PHE PHE VAL LYS LEU TYR PHE THR PHE GLN ASP SEQRES 9 A 312 ASP GLU LYS LEU TYR PHE GLY LEU SER TYR ALA LYS ASN SEQRES 10 A 312 GLY GLU LEU LEU LYS TYR ILE ARG LYS ILE GLY SER PHE SEQRES 11 A 312 ASP GLU THR CYS THR ARG PHE TYR THR ALA GLU ILE VAL SEQRES 12 A 312 SER ALA LEU GLU TYR LEU HIS GLY LYS GLY ILE ILE HIS SEQRES 13 A 312 ARG ASP LEU LYS PRO GLU ASN ILE LEU LEU ASN GLU ASP SEQRES 14 A 312 MET HIS ILE GLN ILE THR ASP PHE GLY THR ALA LYS VAL SEQRES 15 A 312 LEU SER PRO GLU SER LYS GLN ALA ARG ALA ASN SEP PHE SEQRES 16 A 312 VAL GLY THR ALA GLN TYR VAL SER PRO GLU LEU LEU THR SEQRES 17 A 312 GLU LYS SER ALA CYS LYS SER SER ASP LEU TRP ALA LEU SEQRES 18 A 312 GLY CYS ILE ILE TYR GLN LEU VAL ALA GLY LEU PRO PRO SEQRES 19 A 312 PHE ARG ALA GLY ASN GLU TYR LEU ILE PHE GLN LYS ILE SEQRES 20 A 312 ILE LYS LEU GLU TYR ASP PHE PRO GLU LYS PHE PHE PRO SEQRES 21 A 312 LYS ALA ARG ASP LEU VAL GLU LYS LEU LEU VAL LEU ASP SEQRES 22 A 312 ALA THR LYS ARG LEU GLY CYS GLU GLU MET GLU GLY TYR SEQRES 23 A 312 GLY PRO LEU LYS ALA HIS PRO PHE PHE GLU SER VAL THR SEQRES 24 A 312 TRP GLU ASN LEU HIS GLN GLN THR PRO PRO LYS LEU THR MODRES 3QD3 SEP A 241 SER PHOSPHOSERINE HET SEP A 241 10 HET 3Q5 A 360 32 HET SO4 A 1 5 HET GOL A 361 6 HET GOL A 362 6 HETNAM SEP PHOSPHOSERINE HETNAM 3Q5 TERT-BUTYL {(3R,6S)-1-[2-AMINO-6-(3-AMINO-2H-INDAZOL-6- HETNAM 2 3Q5 YL)PYRIMIDIN-4-YL]-6-METHYLPIPERIDIN-3-YL}CARBAMATE HETNAM SO4 SULFATE ION HETNAM GOL GLYCEROL HETSYN SEP PHOSPHONOSERINE HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 1 SEP C3 H8 N O6 P FORMUL 2 3Q5 C22 H30 N8 O2 FORMUL 3 SO4 O4 S 2- FORMUL 4 GOL 2(C3 H8 O3) FORMUL 6 HOH *105(H2 O) HELIX 1 1 ARG A 78 GLU A 80 5 3 HELIX 2 2 LYS A 115 GLU A 121 1 7 HELIX 3 3 LYS A 123 LEU A 137 1 15 HELIX 4 4 GLU A 166 GLY A 175 1 10 HELIX 5 5 ASP A 178 LYS A 199 1 22 HELIX 6 6 THR A 245 VAL A 249 5 5 HELIX 7 7 SER A 250 THR A 255 1 6 HELIX 8 8 CYS A 260 GLY A 278 1 19 HELIX 9 9 ASN A 286 LYS A 296 1 11 HELIX 10 10 PHE A 306 LEU A 317 1 12 HELIX 11 11 ASP A 320 ARG A 324 5 5 HELIX 12 12 CYS A 327 GLU A 331 5 5 HELIX 13 13 GLY A 332 ALA A 338 1 7 HELIX 14 14 HIS A 339 GLU A 343 5 5 HELIX 15 15 ASN A 349 GLN A 353 5 5 SHEET 1 A 5 PHE A 82 GLU A 90 0 SHEET 2 A 5 SER A 94 GLU A 101 -1 O VAL A 96 N LEU A 88 SHEET 3 A 5 GLU A 107 GLU A 114 -1 O ILE A 112 N THR A 95 SHEET 4 A 5 LYS A 154 LEU A 159 -1 O LEU A 155 N LEU A 113 SHEET 5 A 5 LEU A 145 GLN A 150 -1 N PHE A 149 O TYR A 156 SHEET 1 B 2 ILE A 201 ILE A 202 0 SHEET 2 B 2 LYS A 228 VAL A 229 -1 O LYS A 228 N ILE A 202 SHEET 1 C 2 ILE A 211 LEU A 213 0 SHEET 2 C 2 ILE A 219 ILE A 221 -1 O GLN A 220 N LEU A 212 LINK C SEP A 241 N PHE A 242 1555 1555 1.33 SITE 1 AC1 16 HOH A 31 GLU A 90 SER A 94 VAL A 96 SITE 2 AC1 16 ALA A 109 LYS A 111 GLU A 130 MET A 134 SITE 3 AC1 16 LEU A 159 SER A 160 TYR A 161 ALA A 162 SITE 4 AC1 16 LEU A 212 THR A 222 ASP A 223 HOH A 389 SITE 1 AC2 3 ARG A 106 HIS A 351 GOL A 362 SITE 1 AC3 10 ALA A 103 THR A 104 SER A 105 HIS A 139 SITE 2 AC3 10 SER A 191 TRP A 347 GLU A 348 ASN A 349 SITE 3 AC3 10 LEU A 350 HIS A 351 SITE 1 AC4 5 SO4 A 1 HOH A 4 GLU A 107 SER A 160 SITE 2 AC4 5 TYR A 161 CRYST1 123.533 123.533 46.870 90.00 90.00 120.00 P 32 2 1 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.008095 0.004674 0.000000 0.00000 SCALE2 0.000000 0.009347 0.000000 0.00000 SCALE3 0.000000 0.000000 0.021336 0.00000